Examining TLR4+ Blood Cells in Patients with Solid Cancer
Official title: Characterisation of TLR4+ Blood Cells in Patients With Solid Cancer
Run by Hospices Civils de Lyon · NCT06131775 · Data updated 2026-11-12
This study is testing how certain immune cells in the blood can be activated to improve immunotherapy for patients with solid cancers who are just starting treatment.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | Hospices Civils de Lyon Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 4 sites (Bron and 3 other locations) |
| Status | Recruiting |
| Started | May 29, 2024 |
| Main results expected | May 1, 2028 |
| Study ends | May 1, 2028 |
| Registry record updated | May 18, 2025 |
| Trial ID | NCT06131775 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults over 18 with a histologically confirmed diagnosis of solid tumors who are either starting immunotherapy or are eligible for surgery.
✕Probably not a fit
Patients with secondary malignancies or those who have received prior anticancer treatments may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the role of TLR4+ blood cells in patients diagnosed with various types of solid cancers. It aims to understand how these immune cells can be activated to enhance the effectiveness of immunotherapy, particularly in patients who have not previously received immune checkpoint inhibitors. Participants will undergo blood sampling to analyze the characteristics and behavior of these cells in relation to their cancer treatment. The study includes patients with both metastatic and resectable tumors, focusing on those who are initiating immunotherapy.
Why it matters
Potential benefit: If successful, this research could lead to improved immunotherapy strategies for patients with solid tumors, potentially increasing their treatment options and outcomes.
How similar studies have gone: While the approach of examining TLR4+ cells in cancer patients is relatively novel, previous studies have shown promise in utilizing immune system activation for cancer treatment.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient older than 18 years * Patient who gave its written informed consent to participate to the study * Patient with histologically confirmed diagnosis of any type of malignancy (solid tumors) * Patient with a minimum of 6 months life expectation at inclusion * Patient covered by a medical insurance Inclusion criteria specific to cohort 1: \- Patient with metastatic disease or unresectable locally advanced malignancy (solid tumors) who is naive of immune checkpoint inhibitors (ICI)-based immunotherapy and is due to initiate an ICI immunotherapy alone or in combination with any other systemic anticancer treatment. Inclusion criteria specific to cohort 2: \- Patient with a diagnosed malignancy amenable to surgery with curative intent who is naive of any anticancer treatment Exclusion Criteria: * Patient with secondary malignancy unless this malignancy is cured with no evidence of recurrence for at least 5 years. * Pregnant or breastfeeding woman or expecting to conceive * Patient who is deprived of liberty due to judicial or administrative decision * Patient with known psychiatric disorders that would interfere with cooperation with the requirements of the trial * Patient admitted in a social or sanitary institution for an objective other than the one of this trial * Adult patient under legal protection
Where it's running
-
Pneumology Unit
Bron, France Recruiting -
Dermatology Unit
Pierre-Bénite, France Recruiting -
Oncological and Gynecological Surgery Unit,
Pierre-Bénite, France Recruiting -
Oncology Unit, Hospices Civils de Lyon Sud
Pierre-Bénite, France Recruiting
Study contacts
- Study coordinator: Charles DUMONTET, MD
- Email: charles.dumontet@chu-lyon.fr
- Phone: 06 82 13 66 14
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Blood viscosity in ARDS: a look at how thick the blood is
This study tests whether blood viscosity is higher in adults with ARDS and whether viscosity relates to their breathing and blood flow issues.
-
Virus interactions in hospitalized patients during winter seasons in Lyon
This study tests all virological results from hospitalized patients in Lyon during winter to see how different respiratory viruses may co-occur or exclude each other.
-
Surgical Use of Efanoctocog alfa in Hemophilia A Patients
This observational study looks at how efanesoctocog alfa (Altuvoct) is used around surgery in people with hemophilia A to see if it helps control bleeding.
-
Sleep quality and its determinants during the liver transplant pathway
This study tests how sleep quality changes from before liver transplantation to six months after, in adults on the transplant waitlist at a single hospital.
-
Compare Trans-Stomal Bladder Lithotripsy Methods in Continent Catheterizable Urinary Reservoirs
This study looks at different ways to break up bladder stones in people with continent catheterizable urinary diversions to see which method works best when the normal route isn’t available.
-
French version validation of the New Mobility Score for older adults after hip fracture
This study tests whether the French version of the New Mobility Score accurately measures mobility in French patients aged 75 and older after hip fracture.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.